Profound Medical (TSE:PRN) Posts Quarterly Earnings Results

Profound Medical (TSE:PRN) posted its earnings results on Thursday. The company reported C($0.37) earnings per share for the quarter, reports. The business had revenue of C$3.53 million during the quarter. Profound Medical had a negative net margin of 206.94% and a negative return on equity of 78.75%.

Profound Medical Price Performance

PRN stock opened at C$11.10 on Friday. The stock has a market cap of C$403.35 million, a price-to-earnings ratio of -8.95 and a beta of 1.30. The company has a debt-to-equity ratio of 12.56, a current ratio of 6.56 and a quick ratio of 14.98. The company has a 50 day simple moving average of C$9.81 and a 200 day simple moving average of C$9.41. Profound Medical has a 1 year low of C$5.23 and a 1 year high of C$12.40.

Analyst Ratings Changes

Separately, Raymond James Financial upgraded shares of Profound Medical from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, July 27th. Eight research analysts have rated the stock with a Buy rating, fourteen have given a Moderate Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of C$11.10.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.